Treatment Strategies in Disease Progression in ALK+ NSCLC

Opinion
Video

Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  1. Dr.Thawani asks Dr. Kim: If this patient were to progress on lorlatinib, what would be your next treatment approach?
  • What factors would you consider when selecting the next therapy?
Recent Videos
6 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
6 experts are featured in this series.
Related Content
Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

Mobocertinib Does Not Improve PFS Vs Chemotherapy in EGFR Exon 20+ NSCLC

Russ Conroy
February 25th 2025
Article

Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Efficacy results from cohort 1 of the phase 1b Beamion LUNG-1 trial support the decision to review zongertinib in HER2-mutant advanced NSCLC.

Zongertinib Receives FDA Priority Review in HER2–Mutant Advanced NSCLC

Roman Fabbricatore
February 19th 2025
Article

Efficacy results from cohort 1 of the phase 1b Beamion LUNG-1 trial support the decision to review zongertinib in HER2-mutant advanced NSCLC.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective

Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective

ONCOLOGY Staff
February 8th 2025
Article

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Radiation Combo Elicits Efficacy in Advanced NSCLC With Brain Metastases

Roman Fabbricatore
February 6th 2025
Article

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.